Original illustration, not a photograph: PulmoGate raises JPY 330M seed

Nagoya-Linked PulmoGate Raises ¥330M Seed to Scale Online Lung-Disease Second Opinions

November 22, 2026

On 18 November 2026, Nagoya University-linked medtech startup PulmoGate announced a seed round of about ¥330 million, led by Beyond Next Ventures with Teijin Pharma, Mitsubishi UFJ Capital and STATION Ai Central Japan Fund No. 2 also subscribing (PR TIMES release; English coverage by The SaaS News on 20 November 2026).

About the author: Jason Lim is a venture builder who, per his own site authorjason.com, has coached and mentored founders since 2016 across Singapore, Malaysia, China, Taiwan and Indonesia (self-described). See his program page for a free consultation.

Promotion

A funding announcement is a useful moment to look at how your own story is told. Jason Lim's Future of Selling — Presentation Skills Coaching Program teaches a five-step method, P.I.T.C.H. (Power, Intent, Teach, Close, Habits, as described on the program page), and the page sets out what to expect so you can read the details and judge the fit in your own time. Entry is by application, with a free consultation first and a limited number of private spots each quarter: a chance to ask your questions and be heard before you decide.

See the program page and the free consultation

The company was founded in November 2025 in Nagoya and is led by representative director and CEO 富永 朋. Its first target is interstitial lung disease (ILD), a group of conditions in which inflammation and scarring stiffen the lungs. The company's own announcement is also on its news page.

A Service First, Research Second

What is live today is a service, not a device. Partner medical institutions can run online second opinions for ILD, supported by remote multidisciplinary team discussions (MDD) and built on the system base of the PROMISE trial, in which Nagoya University led online MDD and examined its usefulness. Diagnosis candidates, suggested additional tests and treatment discussion points reach the attending physician as a report (per the release). The company's diagnostic AI, treatment-strategy AI and home-support app remain at the research-and-development stage and are not approved medical devices; the release states this itself.

The Clinical Problem, With Sources

The release cites its figures and names its sources. ILD was the 11th leading cause of death in Japan in the health ministry's 2025 vital statistics (as cited in the release). Prevalence roughly doubled, from 656 to 1,301 people per 100,000, between 2015 and 2023. Five-year survival is 59.9% across ILD and 32.1% for idiopathic pulmonary fibrosis (Miyashita et al., Respiratory Investigation 2026, as cited). Care guidelines call for a multidisciplinary team of respiratory physicians, radiologists and, when needed, pathologists, which few single hospitals can assemble.

What the Investors Said

Paraphrased from the release: Beyond Next Ventures partner 橋爪 克弥 says MDD is recommended for ILD diagnosis but only a small share of patients receive it, and that his firm has prepared with co-founder and chief medical officer Dr. 古川 大記 to turn his Nagoya University research into a business since meeting him in 2022. Teijin Pharma's president points to the company's long history in home oxygen therapy. Mitsubishi UFJ Capital's 加藤 遼 hopes the remote-MDD implementation and AI development will help solve clinical challenges. STATION Ai's representative cites Dr. Furukawa's commitment and the CEO's record of building businesses.

Where the Money Goes

The release lists three uses of funds: expanding the facilities offering ILD online second opinions on the remote-MDD platform; development, validation, clinical evaluation and regulatory preparation for the diagnostic AI; and research, development and clinical evaluation for the treatment-strategy AI and the home monitoring and rehabilitation support. These are plans, not results.

Promotion

What could you aim to practise after reading this story? A one-sentence pitch a non-specialist can repeat, evidence kept apart from opinion, and a close that names the next step. The program page lists its steps in order, so you can see the structure before you commit and check the facts at your own pace. If you would rather talk it through with a person first, the free consultation is the place to start.

Review the steps on the program page

Related News

Four Presentation Lessons From This Story

Editorial analysis, offered conditionally. Every team and room differs.

1. Say what the service does in plain words. An illustrative sentence built from the release, not company language: "PulmoGate lets hospitals offer patients an online panel of specialists for lung-disease diagnosis, starting with interstitial lung disease." If a listener needs a paragraph before understanding your product, cut until one sentence carries it.

2. Separate what ships from what is still research. A live service first and AI development second, each labelled honestly, gives a non-specialist a structure to follow. Investors who see the structure can check your facts at their own pace instead of guessing.

3. Anchor every number to a named source. The release pairs its figures with a health-ministry statistic and a journal citation. In your own deck, write the number, the source and the date.

4. Prepare for the follow-up as carefully as the pitch. If investors go quiet after a meeting, a short message with one new fact and one clear next step is easier to answer than a long reminder. The mixed investor group here, from a venture fund to a pharmaceutical company, is a reminder that different listeners look for different proof.

Advertisement

DreamakerAI describes itself as an all-in-one AI CRM and "business OS" for founders, with CRM, funnels, websites, AI agents, WhatsApp and SEO tools in one place, so you can see how the pieces fit. Founders who want a clearer view of their customer conversations and next opportunities can read the details at their own pace and check current pricing on the page.

Disclaimers. The diagnostic AI, treatment-strategy AI and home-support app described in the release are at the research-and-development stage and have not been approved as medical devices. Figures come from the company's release and the sources it cites; we have not independently verified them. Editorial analysis is ours, not the company's. PulmoGate has not endorsed any program mentioned here. Nothing here is investment or medical advice.

A Rare Window of Opportunity for Singapore, China and Asia Startups

In the Chapman University Survey of American Fears, Wave 11 (fieldwork 24 March–8 April 2025, n=1,015 U.S. adults, self-reported, a U.S. sample), 33.7% of respondents said they were afraid or very afraid of public speaking (complete ranked list, PDF). That is a figure about Americans in general, not about founders or investors.

The opening this story suggests is narrow and conditional: a specific clinical problem, a university research base and a mixed group of investors came together in one seed round. Whether that signals wider cross-border interest in Asian health-tech is not something these sources establish. What founders in Singapore, China and across Asia can control is how clearly they present their own case. Clear, honest communication may help them make use of whatever openings arise; it guarantees nothing.

Promotion

The aim worth setting is to explain a hard idea so clearly that the right listeners can act on it. That is a skill built step by step, and the program page shows the five steps and what each covers. Entry is by application and spots are limited each quarter; the free consultation lets you ask questions first. Results vary by person and effort, and nothing here is a guarantee.

Book your free consultation on the program page

Jason Lim

Jason Lim

I wanted more than just survival—I wanted control, options, and a life on my terms. The obsession with this goal led me to several places and acquired unique skillsets, in order to accomplish my goals. I found the secrets in my rock bottom, now I want to share them with you

Instagram logo icon
Youtube logo icon
Back to Blog